{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:08:07Z","timestamp":1779246487807,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75304-5","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T13:02:31Z","timestamp":1729256551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cognivue Clarity characterizes mild cognitive impairment and Alzheimer\u2019s disease in biomarker confirmed cohorts in the Bio-Hermes Study"],"prefix":"10.1038","volume":"14","author":[{"given":"James E.","family":"Galvin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Kleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Estes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"75304_CR1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dementia  19(4), 1598\u20131695 (2023).","DOI":"10.1002\/alz.13016"},{"issue":"1","key":"75304_CR2","first-page":"7","volume":"11","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Jun, H., Becker, A., Wallick, C. & Mattke, S. Detection of rates of mild cognitive impairment in primary care for the United States Medicare population. J. Prev. Alzheimer Dis.  11 (1), 7\u201312 (2024).","journal-title":"J. Prev. Alzheimer Dis."},{"key":"75304_CR3","doi-asserted-by":"publisher","first-page":"960648","DOI":"10.3389\/fpsyt.2022.960648","volume":"13","author":"M Casagrande","year":"2020","unstructured":"Casagrande, M. et al. The complex burden of determining prevalence rates of mild cognitive impairment: A systematic review. Front. Psychiatry 13, 960648 (2020).","journal-title":"Front. Psychiatry"},{"issue":"1","key":"75304_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13670-018-0236-2","volume":"7","author":"JE Galvin","year":"2018","unstructured":"Galvin, J. E. Using informant and performance screening methods to detect mild cognitive impairment and dementia. Curr. Geriatr. Rep. 7(1), 19\u201325 (2018).","journal-title":"Curr. Geriatr. Rep."},{"issue":"4","key":"75304_CR5","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/alz.13722","volume":"20","author":"RC Mohs","year":"2024","unstructured":"Mohs, R. C. et al. The Bio-hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer\u2019s disease. Alzheimers Dement. 20(4), 2752\u20132765 (2024).","journal-title":"Alzheimers Dement."},{"key":"75304_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-240331","volume":"100","author":"JE Galvin","year":"2024","unstructured":"Galvin, J. E., Chang, L. C., Estes, P., Harris, H. M. & Fung, E. Cognitive assessment with Cognivue clarity: Psychometric properties and normative ranges in a diverse population. J. Alzheimers Dis. 100, 509\u2013523 (2024).","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"75304_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5498\/wjp.v10.i1.1","volume":"10","author":"D Cahn-Hidalgo","year":"2020","unstructured":"Cahn-Hidalgo, D., Estes, P. W. & Benabou, R. Validity, reliability, and psychometric properties of a computerized, cognitive assessment test (Cognivue). World J. Psychiatry 10(1), 1\u201311 (2020).","journal-title":"World J. Psychiatry"},{"issue":"3","key":"75304_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12(3), 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"75304_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA Research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14(4), 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"issue":"3","key":"75304_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7(3), 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"issue":"3","key":"75304_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7(3), 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"issue":"3","key":"75304_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4","volume":"40","author":"SJ Rosenberg","year":"1984","unstructured":"Rosenberg, S. J., Ryan, J. J. & Prifitera, A. Rey auditory-verbal learning test performance of patients with and without memory impairment. J. Clin. Psychol. 40 (3), 785\u2013787 (1984).","journal-title":"J. Clin. Psychol."},{"issue":"3","key":"75304_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37 (3), 323\u2013329 (1982).","journal-title":"J. Gerontol."},{"key":"75304_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","volume":"519","author":"KM Kirmess","year":"2021","unstructured":"Kirmess, K. M. et al. The PrecivityAD\u2122 test: accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin. Chim. Acta. 519, 267\u2013275 (2021).","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"75304_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-021-00234-5","volume":"10","author":"X Ding","year":"2021","unstructured":"Ding, X. et al. Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: A systematic review and meta-analysis. Transl. Neurodegener. 10 (1), 1\u201314 (2021).","journal-title":"Transl. Neurodegener."},{"issue":"2","key":"75304_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 78(2), 149\u2013156 (2021).","journal-title":"JAMA Neurol."},{"issue":"10","key":"75304_CR17","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton, H. G. et al. Quantification of amyloid PET for future clinical use: A state-of-the-art review. Eur. J. Nucl. Med. Mol. Imaging 49 (10), 3508\u20133528 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"75304_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","volume":"19","author":"Y Su","year":"2018","unstructured":"Su, Y. et al. Utilizing the centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage Clin. 19, 406\u2013416 (2018).","journal-title":"NeuroImage Clin."},{"issue":"1","key":"75304_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N Engl. J. Med. 388 (1), 9\u201321 (2023).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"75304_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330 (6), 512\u2013527 (2023).","journal-title":"JAMA"},{"issue":"11","key":"75304_CR21","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1093\/brain\/awq204","volume":"33","author":"JE Galvin","year":"2010","unstructured":"Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A. & Morris, J. C. Relationship of dementia screening tests with biomarkers of Alzheimer\u2019s disease. Brain 33 (11), 3290\u20133300 (2010).","journal-title":"Brain"},{"key":"75304_CR22","doi-asserted-by":"crossref","unstructured":"Groechel, R. C. et al. Biomarkers of Alzheimer\u2019s disease in Black and\/or African American Alzheimer\u2019s disease neuroimaging initiative (ADNI) participants. Neurobiol. Aging 131, 144\u2013152 (2023).","DOI":"10.1016\/j.neurobiolaging.2023.07.021"},{"key":"75304_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.26819","volume":"95","author":"JD Grill","year":"2024","unstructured":"Grill, J. D. et al. Eligibility rates among racially and ethnically diverse US participants in phase 2 and phase 3 placebo-controlled, double-blind, randomized trials of Lecanemab and Elenbecestat in Early Alzheimer disease. Ann. Neurol. 95, 288\u2013298 (2024).","journal-title":"Ann. Neurol."},{"key":"75304_CR24","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179\u20133192 (2024).","journal-title":"Alzheimers Dement."},{"key":"75304_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.biopsych.2013.11.032","volume":"75","author":"O Harari","year":"2014","unstructured":"Harari, O. et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer\u2019s disease in multiplex immunoassay panels of cerebrospinal fluid. Biol. Psychiatry 75, 723\u2013731 (2014).","journal-title":"Biol. Psychiatry"},{"key":"75304_CR26","doi-asserted-by":"publisher","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow, K. et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1\u201342), pTau and tTau CSF immunoassays. Sci. Rep. 9, 19024 (2019).","journal-title":"Sci. Rep."},{"key":"75304_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2024.08.007","volume":"143","author":"V Quaresima","year":"2024","unstructured":"Quaresima, V. et al. Plasma p-tau181 and amyloid markers in Alzheimer\u2019s disease: A comparison between Lumipulse and SIMOA. Neurobiol. Aging 143, 30\u201340 (2024).","journal-title":"Neurobiol. Aging"},{"key":"75304_CR28","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for cognitive impairment in older adults: US preventive services task force recommendation statement. JAMA 323(8), 757\u2013763 (2020).","DOI":"10.1001\/jama.2020.0435"},{"issue":"2","key":"75304_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/gps.5016","volume":"34","author":"A Breton","year":"2019","unstructured":"Breton, A., Casey, D. & Arnaoutoglou, N. A. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int. J. Geriatr. Psychiatry. 34 (2), 233\u2013242 (2019).","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"3","key":"75304_CR30","first-page":"165","volume":"7","author":"MN Sabbagh","year":"2020","unstructured":"Sabbagh, M. N. et al. Early detection of mild cognitive impairment (MCI) in primary care. J. Prev. Alzheimer\u2019s Dis. 7 (3), 165\u2013170 (2020).","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"1","key":"75304_CR31","first-page":"CD011145","volume":"2016","author":"ST Creavin","year":"2016","unstructured":"Creavin, S. T. et al. Mini-mental state examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst. Rev. 2016 (1), CD011145 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"75304_CR32","doi-asserted-by":"crossref","unstructured":"Ramos-Henderson, M., Calder\u00f3n, C. & Domic-Siede, M. Education bias in typical brief cognitive tests used for the detection of dementia in elderly population with low educational level: a critical review. Appl. Neuropsychol. Adult 2022 Dec. 15:1\u20139 .","DOI":"10.1080\/23279095.2022.2155521"},{"key":"75304_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3233\/ADR-230194","volume":"8","author":"T Chithiramohan","year":"2024","unstructured":"Chithiramohan, T. et al. Culture-fair cognitive screening tools for assessment of cognitive impairment: A systematic review. J. Alzheimers Dis. Rep. 8, 289\u2013306 (2024).","journal-title":"J. Alzheimers Dis. Rep."},{"key":"75304_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/ageing\/afh135","volume":"33","author":"C Parker","year":"2004","unstructured":"Parker, C. & Philp, I. Screening for cognitive impairment among older people in black and minority ethnic groups. Age Ageing 33, 447\u2013452 (2004).","journal-title":"Age Ageing"},{"key":"75304_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7748\/nop2007.01.18.12.31.c4359","volume":"18","author":"C Parker","year":"2007","unstructured":"Parker, C., Philp, I., Sarai, M. & Rauf, A. Cognitive screening for people from minority ethnic backgrounds. Nurs. Older People 18, 31\u201336 (2007).","journal-title":"Nurs. Older People"},{"key":"75304_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1212\/CPJ.0000000000000566","volume":"9","author":"JM Ranson","year":"2019","unstructured":"Ranson, J. M. et al. Predictors of dementia misclassification when using brief cognitive assessments. Neurol. Clin. Pract. 9, 109\u2013117 (2019).","journal-title":"Neurol. Clin. Pract."},{"key":"75304_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/alz.12773","volume":"19","author":"RJ Jutten","year":"2023","unstructured":"Jutten, R. J. et al. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer\u2019s disease. AAlzheimers Dement. 19, 708\u2013720 (2023).","journal-title":"Alzheimers Dement."},{"key":"75304_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-023-01367-7","volume":"16","author":"A Jannati","year":"2024","unstructured":"Jannati, A. et al. Digital clock and recall is superior to the mini-mental state examination for the detection of mild cognitive impairment and mild dementia. Alzheimers Res. Ther. 16, 2 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"75304_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jalz.2012.09.011","volume":"9","author":"CB Cordell","year":"2013","unstructured":"Cordell, C. B. et al. Medicare Detection of Cognitive Impairment Workgroup. Alzheimer\u2019s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 9, 141\u2013150 (2013).","journal-title":"Alzheimers Dement."},{"key":"75304_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/10775587231166037","volume":"80","author":"MK Hamer","year":"2023","unstructured":"Hamer, M. K., DeCamp, M., Bradely, C. J., Nease, D. E. Jr & Perraillon, M. C. Adoption and value of the Medicare annual wellness visit: A mixed-methods study. Med. Care Res. Rev. 80, 433\u2013443 (2023).","journal-title":"Med. Care Res. Rev."},{"key":"75304_CR41","doi-asserted-by":"publisher","first-page":"100577","DOI":"10.1016\/j.ssmph.2020.100577","volume":"11","author":"JM Hale","year":"2020","unstructured":"Hale, J. M., Schneider, D. C., Mehta, N. K. & Myrskyl\u00e4, M. Cognitive impairment in the US: Lifetime risk, age at onset, and years impaired. SSM-Population Health 11, 100577 (2020).","journal-title":"SSM-Population Health"},{"issue":"2","key":"75304_CR42","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3233\/JAD-220891","volume":"91","author":"MJ Kleiman","year":"2023","unstructured":"Kleiman, M. J., Ariko, T., Galvin, J. E. & Alzheimer\u2019s Disease Neuroimaging Initiative. Hierarchical two-stage cost-sensitive clinical decision support system for screening prodromal Alzheimer\u2019s disease and related dementias. J. Alzheimers Dis. 91(2), 895\u2013909 (2023).","journal-title":"J. Alzheimers Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75304-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75304-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75304-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T13:04:13Z","timestamp":1729256653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75304-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75304"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75304-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4875076\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JEG is a full-time employee of the University of Miami Miller School of Medicine and serves as Chief Scientific Officer for Cognivue, Inc receiving consulting fees. MJK is a full-time employee of the University of Miami Miller School of Medicine and received consulting fees from Cognivue, Inc to conduct statistical analyses. PWE, HMH, and EF are full-time employees of Cognivue, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol was reviewed and approved by Advarra, a central institutional review board (Reference Number Pro00046018). The study was registered on ClinicalTrials.gov (NCT04733989) on 2\/2\/2021. Research was conducted in accordance with the Declaration of Helsinki. Prior to any data collection, all participants signed written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"24519"}}